Prothena Corporation PLC (PRTA) was Initiated by Barclays to “Overweight” and the brokerage firm has set the Price Target at $60. Barclays advised their investors in a research report released on May 13, 2016.
Many Wall Street Analysts have commented on Prothena Corporation PLC. Shares were Reiterated by Wedbush on Feb 19, 2016 to “Outperform” and Lowered the Price Target to $ 77 from a previous price target of $81 .
On the company’s financial health, Prothena Corporation PLC reported $-0.76 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Feb 18, 2016. Analyst had a consensus of $-0.80. The company had revenue of $.31 million for the quarter, compared to analysts expectations of $.39 million. The company’s revenue was down -83.6 % compared to the same quarter last year.
Prothena Corporation PLC opened for trading at $39.36 and hit $41.49 on the upside on Tuesday, eventually ending the session at $40.74, with a gain of 4.35% or 1.7 points. The heightened volatility saw the trading volume jump to 4,47,066 shares. Company has a market cap of $1,399 M.
In a different news, on Apr 15, 2016, Karin L Walker (officer ) sold 4,000 shares at $45.23 per share price. According to the SEC, on Apr 6, 2016, Dennis J. Selkoe (director) sold 5,000 shares at $45.00 per share price. On Jan 6, 2016, Arthur W Homan (Chief Legal Officer) sold 3,125 shares at $65.50 per share price, according to the Form-4 filing with the securities and exchange commission.
Prothena Corporation Public Limited Company is an Ireland-based late-stage clinical biotechnology company. The Company is focused on the discovery development and commercialization of protein immunotherapy programs for the treatment of diseases that involve amyloid or cell adhesion. The Company’s research and development pipeline includes three therapeutic antibody programs such as NEOD001 for the treatment of AL amyloidosis; PRX002 in collaboration with Roche for the treatment of Parkinson’s disease and other related synucleinopathies and PRX003 for the treatment of psoriasis and other inflammatory diseases. The Company’s pipeline also includes several late discovery stage programs for which it is testing antibodies in preclinical models of diseases related to amyloid or cell adhesion.